Background {#S1}
==========

Macrolides are mainly used as antibiotics to treat respiratory, skin and soft tissue, and urogenital infections ([@B1], [@B2]). They derive from *Streptomyces* species and are characterized by a macrocyclic lactone ring, which is either 14- \[erythromycin (ERM), clarithromycin (CAM) and roxithromycin (RXM)\], 15- \[azithromycin (AZM)\], or 16-membered (spiramycin, josamycin, midecamycin) ([@B3]). The antimicrobial activity of macrolides results from inhibition of bacterial protein synthesis through reversible binding to the peptide exit tunnel of ribosomes ([@B4]).

In addition to their antibiotic activity, macrolides have immunomodulatory properties, which were first described soon after their introduction in the 1950s ([@B3], [@B5]--[@B7]). The concept of using macrolides primarily for their immunomodulatory activities was introduced in the 1970s ([@B8]). The seminal study that distinguished between macrolides' antimicrobial and their immunomodulatory effects was in adults with diffuse panbronchiolitis (DPB) in whom treatment with ERM dramatically improved survival independent of bacterial colonization ([@B9]). These results encouraged further research on the use of macrolides for the treatment of other chronic inflammatory conditions ([@B10]--[@B14]).

The mechanisms underlying the non-antimicrobial effects of macrolides are less well understood. Aside from ribosomal-mediated inhibition of pathogen virulence factor production, a number of other mechanisms have been proposed, including action on host immunity.

The objective of this review was to systematically summarize studies which investigated immunomodulatory properties of macrolides in humans and to describe the underlying mechanism and extent of their influence on the innate and adaptive immune system.

Methods {#S2}
=======

This review was done according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) ([@B15]). A literature review was done in December 2016 searching MEDLINE using the OVID interface from 1946 to 2016 using the search terms: (macrolide OR azithromycin OR clarithromycin OR erythromycin OR roxithromycin) AND (anti-inflammatory OR immunomodulatory OR immunolides) without any language limitations or limitation of study design (Figure [1](#F1){ref-type="fig"}). Only studies in humans, in which the participants received one of the four mentioned macrolides and which investigated immunological markers involved in inflammation were included. Studies reporting clinical endpoints only or studies in which macrolides were investigated for their antimicrobial activity were excluded. References were hand-searched for additional publications. Search results were independently screened by one reviewer, and checked by a second reviewer. Potentially eligible full-text articles were assessed according to our inclusion and exclusion criteria. The following variables were extracted from the included studies: year of study, country, study design, number of participants, age of participants, underlying disease, type, dose and duration of macrolide use, type of samples collected, and measured immune markers. Changes were classified as being significant when the *p*-value was ≤0.05.

![Selection of articles included in the review.](fimmu-09-00302-g001){#F1}

Review {#S3}
======

Characteristics of Included Studies {#S3-1}
-----------------------------------

We identified 2,107 studies, of which 45 were included in the final analysis; 22 randomized, controlled trials, 16 prospective cohort studies, and 7 case--control studies (Figure [1](#F1){ref-type="fig"}). Studies originated from 17 countries (Japan *n* = 12, United States of America *n* = 6, China *n* = 4, Australia *n* = 4, United Kingdom *n* = 4, Turkey *n* = 2, Serbia *n* = 2, Croatia *n* = 2, and one each from Belgium, Canada, Greece, the Netherlands, Italy, South Korea, Russia, Sweden, and Switzerland) and included a total of 1,834 participants. Six studies, including 423 participants, were done in children and adolescents (\<18 years of age). Details of all studies including a risk of bias analysis are summarise in Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}.

###### 

Macrolide-induced changes in immunological markers in 45 studies in humans categorized by disease (NS = not stated).

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                                 Drug                                                                                                     Dose                                   Duration (weeks)   Patients (healthy) (*n*)   Age (years) (mean)          Sample                                                                                             Measured immune markers                                                                                  Study design                   Reference
  -------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------ -------------------------- --------------------------- -------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------ --------------------------
  Blepharitis                                                                                                    AZM                                                                                                      1% topical drops                       4                  24 (8)                     34--80 (54)                 Conjunctival cells                                                                                 Decrease in IL-1beta, IL-8, matrix metalloproteinase 9 (MMP-9)                                           CCS                            Zhang et al. ([@B16])

  Eyelid margins                                                                                                 Increase in TGF-beta                                                                                                                                                                                                                                                                                                                                                                                                                                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Periodontitis                                                                                                  RXM                                                                                                      300 mg daily                           0.7                47 (16)                    28--65 (46)                 Gingival cervicular fluid                                                                          Decrease in IL-1beta, TGF-beta, VEGF                                                                     RCT                            Gong et al. ([@B18])

  Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Nasal polyps                                                                                                   CAM                                                                                                      500 mg daily                           8                  40                         25--73 (44)                 Nasal secretions                                                                                   Decrease in CCL-5 in allergic and non-allergic patients                                                  PCS                            Peric et al. ([@B19])

  Decrease in IL-6 in allergic patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Decrease in ECP in non-allergic patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            500 mg daily                                                                                             8                                      40                 25--73 (44)                Nasal secretions            Decrease in IL-8 in allergic and non-allergic patients                                             PCS                                                                                                      Peric et al. ([@B20])          

  Decrease in IL-1beta, IL-6 in allergic patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Decrease in TNF-alpha in non-allergic patients                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            400 mg daily                                                                                             12                                     20                 28--84 (57)                Nasal secretions            Decrease in IL-8                                                                                   PCS                                                                                                      Yamada et al. ([@B21])         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Rhinosinusitis                                                                                                 CAM                                                                                                      500 mg BID                             2                  25                         19--70 (45)                 Nasal mucosa cells                                                                                 Decrease in macrophage count, eosinophil activity, neutrophil elastase, IL-6, IL-8, and TNF-alpha        PCS                            MacLeod et al. ([@B22])

  CAM                                                                                                            250 mg daily                                                                                             12                                     30                 25--63 (46)                Nasal secretions            Decrease in IL-8, ECP                                                                              PCS                                                                                                      Cervin et al. ([@B23])         

  Decrease in MPO, alpha2-macroglobulin (not significant)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  CAM                                                                                                            250 mg daily                                                                                             12                                     10                 27--62 (48)\*              Nasal mucosa cells          Decrease in TGF-beta, NF-kappaB (not significant)                                                  PCS                                                                                                      Wallwork et al. ([@B24])       

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            250 mg daily                                                                                             52                                     17                 18--67 (51)                Nasal mucosa cells          Increase in nasal nitric oxide (not significant)                                                   PCS                                                                                                      Cervin et al. ([@B59])         

  ERM                                                                                                            250 mg BID                                                                                                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  RXM                                                                                                            150 mg daily                                                                                             1--46                                  12                 16--73 (54)                Nasal secretions            Decrease in neutrophil count, IL-8                                                                 PCS                                                                                                      Suzuki et al. ([@B25])         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  RXM                                                                                                            150 mg daily                                                                                             12                                     64                 \>18                       Nasal secretions            Decrease in IL-8                                                                                   RCT                                                                                                      Wallwork et al. ([@B26])       

  Placebo                                                                                                        Nasal mucosa cells                                                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Asthma\                                                                                                        AZM                                                                                                      250 mg daily                           12                 71                         18--70 (43)                 Sputum                                                                                             No change in eosinophil count, neutrophil count                                                          RCT                            Cameron et al. ([@B27])
  Bronchiale                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  AZM                                                                                                            NS                                                                                                       12                                     40                 22--52 (35)                Sputum                      Decrease in IL-4, IL-5, IFN-gamma                                                                  RCT                                                                                                      He et al. ([@B28])             

  Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  AZM                                                                                                            10 mg/kg daily, 3 times a week                                                                           8                                      16                 NS (13)                    BAL                         Decrease in neutrophil count                                                                       RCT                                                                                                      Piacentini et al. ([@B29])     

  Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            15 mg/kg BID (max 500 mg)                                                                                0.7                                    43                 4--17 (9)                  Nasopharyngeal secretions   Decrease in TNF-alpha, IL-1, IL-10                                                                 RCT                                                                                                      Fonseca-Aten et al. ([@B30])   

  Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            200 mg BID                                                                                               8                                      17                 26--49 (38)                Sputum                      Decrease in eosinophil count, ECP                                                                  RCT                                                                                                      Amayasu et al. ([@B31])        

  Placebo                                                                                                        Blood                                                                                                    Decrease in eosinophil count, ECP                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            500 mg BID                                                                                               6                                      86                 NS (33)                    BAL                         Decrease in TNF-alpha, IL-5, IL-12                                                                 RCT                                                                                                      Kraft et al. ([@B32])          

  Placebo                                                                                                        Airway tissue                                                                                            Decrease in TNF-alpha, IL-5, IL-12                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            500 mg BID                                                                                               8                                      45                 27--80 (58)                Sputum                      Decrease in neutrophil count, neutrophil elastase, IL-8                                            RCT                                                                                                      Simpson et al. ([@B33])        

  Placebo                                                                                                        Decrease in MMP-9 (not significant)                                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            500 mg BID                                                                                               8                                      45                 27--80 (60)                Sputum                      Decrease in neutrophil count, neutrophil elastase, MMP-9, IL-8                                     RCT                                                                                                      Wang et al. ([@B34])           

  Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  RXM                                                                                                            150 mg BID                                                                                               8                                      14                 29--50 (40)                Sputum                      Decrease in eosinophil count, ECP                                                                  RCT                                                                                                      Shoji et al. ([@B35])          

  Placebo                                                                                                        Blood                                                                                                    Decrease in eosinophil count, ECP                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  RXM                                                                                                            150 mg daily                                                                                             12                                     20 (10)            NS (41)                    PMNL                        Decrease in neutrophil oxidative burst                                                             PCS                                                                                                      Kamoi et al. ([@B36])          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Bronchiectasis                                                                                                 CAM                                                                                                      500 mg daily                           12                 22                         32--78 (58)                 Blood                                                                                              Decrease in Th17-cells, IL-17                                                                            PCS                            Fouka et al. ([@B37])

  CAM                                                                                                            15 mg/kg daily                                                                                           12                                     34                 7--18 (13)                 BAL                         Decrease in total cell count, neutrophil count, IL-8                                               RCT                                                                                                      Yalcin et al. ([@B38])         

  Supportive treatment                                                                                           Increase in macrophage count                                                                                                                                                                                                                                                                                                                                                                                                                                         

  RXM                                                                                                            150 mg daily                                                                                             26                                     52                 18--65 (48)                Sputum                      Decrease in neutrophil count, neutrophil elastase, IL-8, MMP-9                                     RCT                                                                                                      Liu et al. ([@B39])            

  No treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Chronic obstructive pulmonary disease                                                                          AZM\                                                                                                     500 mg daily                           0.4                24                         35--70 (62)                 Blood                                                                                              Increase in neutrophil oxidative burst                                                                   RCT                            Parnham et al. ([@B40])
                                                                                                                 Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                 Decrease in leukocyte count, thrombocyte count, IL-8, E-selectin, CRP, lactoferrin, serum amyloid A                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                          No change in TNF-alpha, IL-6, GM-CSF                                                                                                                                                                                                                                                                                                                        

  Sputum                                                                                                         No change in neutrophil count, eosinophil count                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            500 mg daily                                                                                             12                                     67                 NS (65)                    Sputum                      Decrease in neutrophil chemotaxis (not significant)                                                RCT                                                                                                      Banerjee et al. ([@B41])       

  Placebo                                                                                                        No change in total cell count, neutrophil count, IL-8, leukotriene B 4, TNF-alpha, neutrophil elastase                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  ERM\                                                                                                           125 mg TDS                                                                                               24                                     36                 ≥40 (69)                   Sputum                      Decrease in total cell count, neutrophil count, neutrophil elastase                                RCT                                                                                                      He et al. ([@B42])             
  Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Diffuse panbronchiolitis                                                                                       ERM                                                                                                      250 mg BID                             ≥24                14                         NS (46)                     BAL                                                                                                Decrease in lymphocyte count, IL-2, IFN-gamma\                                                           PCS                            Park et al. ([@B43])
                                                                                                                                                                                                                                                                                                                                                                                                                                              Increase in CD4/CD8 ratio, IL-4, IL-5, IL-13                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  ERM                                                                                                            200 mg TDS                                                                                               24--52                                 18 (5)             14--63 (39)                BAL                         Decrease in total cell count, neutrophil count, neutrophil chemotaxis                              CCS                                                                                                      Oda et al. ([@B44])            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  ERM                                                                                                            NS TDS                                                                                                   24--52                                 19                 NS (42)                    BAL                         Decrease in total cell count, neutrophil count, neutrophil chemotaxis                              CCS                                                                                                      Kadota et al. ([@B45])         

  ERM                                                                                                            200 mg TDS                                                                                               8--68                                  22 (5)             18--70 (45)                BAL                         Decrease in neutrophil count, neutrophil chemotaxis, IL-8                                          CCS                                                                                                      Katsuki et al. ([@B46])        

  No change in TNF-alpha                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  ERM                                                                                                            600 mg daily                                                                                             12                                     12                 16--75 (47)                BAL                         Decrease in neutrophil count, neutrophil elastase                                                  CCS                                                                                                      Ichikawa et al. ([@B47])       

  Amoxicillin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  ERM                                                                                                            600 mg daily                                                                                             4--104                                 43 (7)             \(47\)                     BAL                         Decrease in neutrophil count, IL-1beta, IL-8                                                       CCS                                                                                                      Sakito et al. ([@B48])         

  RXM                                                                                                            150 mg daily                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  ERM                                                                                                            400 mg daily                                                                                             12                                     12 (6)             NS                         Blood                       Decrease in neutrophil oxidative burst                                                             CCS                                                                                                      Umeki ([@B49])                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Cystic fibrosis                                                                                                AZM                                                                                                      NS                                     4                  260                        6--18 (NS)                  Blood                                                                                              Decrease in neutrophil count, MPO, high-sensitivity C reactive protein, serum amyloid A, calprotection   RCT                            Ratjen et al. ([@B50])

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  AZM                                                                                                            250 mg daily (≤ 40 kg)                                                                                   24                                     41                 8--18 (NS)                 Sputum                      Decrease in IL-8, neutrophil elastase (not significant) (data only available from 17 patients)     RCT                                                                                                      Equi et al. ([@B51])           

  500 mg daily (\> 40 kg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            7.5 mg/kg BID                                                                                            12                                     18                 3--15 (9)                  BAL                         Decrease in neutrophil count, neutrophil elastase (not significant)                                RCT                                                                                                      Doğru et al. ([@B52])          

  Increase in macrophage count (not significant)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  CAM                                                                                                            250 mg daily                                                                                             52                                     27                 6--17 (12)                 Sputum                      Decrease in IL-4, IL-8, TNF-alphaDecrease in INF-gamma (not significant)                           PCS                                                                                                      Pukhalsky et al. ([@B53])      

  Blood                                                                                                          Decrease in IL-4, IL-8, TNF-alpha                                                                                                                                                                                                                                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Lung transplantation                                                                                           AZM                                                                                                      NS                                     12--24             30                         36--61 (56)                 BAL                                                                                                Decrease in neutrophil count, IL-8, MMP-9                                                                PCS                            Verleden et al. ([@B54])

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Diabetic nephropathy                                                                                           CAM                                                                                                      200 mg daily                           12                 16                         NS (67)                     Urine                                                                                              Decrease CCL-2                                                                                           RCT                            Tone ([@B60])

  Placebo                                                                                                        Blood                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Coronary atherosclerosis                                                                                       CAM                                                                                                      500 mg daily                           8                  231                        NS (65)                     Blood                                                                                              Decrease in CRP, IL-2, IL-6, IL-8, TNF-alpha (not significant)                                           RCT                            Berg et al. ([@B55])

  Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Healthy volunteers                                                                                             AZM                                                                                                      500 mg daily                           0.4                12                         24--45 (29)                 Blood                                                                                              Increase in neutrophil oxidative burst, apoptosis of neutrophils                                         PCS                            Culić et al. ([@B56])

  Increase in TNF-alpha (not significant)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Decrease in IL-1beta, IL-6, IL-8, myeloperoxidase, IL-17, soluble vascular cell adhesion molecule-1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Decrease in E-selectin, lactoferrin (not significant)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  No change in leukocyte count, thrombocyte count, neutrophil elastase, beta2-microglobulin, INF-gamma, GM-CSF                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  AZM                                                                                                            500 mg on day 1, then 250 mg                                                                             0.7                                    12                 23--47 (30)                Sputum                      No change in total cell count, neutrophil count, IL-6, IL-8 after ozone exposure during exercise   RCT                                                                                                      Criqui et al. ([@B57])         

  Placebo                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  AZM                                                                                                            500 mg daily                                                                                             0.4                                    19                 18--40 (25)                BAL                         No change in TNF-alpha, IL-1beta, IL-6, superoxide generation by alveolar macrophages              PCS                                                                                                      Aubert et al. ([@B58])         

  Blood                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  AZM                                                                                                            500 mg daily first day, then 250 mg daily                                                                0.4                                    10                 NS (30)                    Gingival cervicular fluid   Decrease in IL-1beta, IL-8, TNF-alpha, VEGF                                                        PCS                                                                                                      Ho et al. ([@B17])             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Risk of bias summary of the randomized controlled trials and case--control studies included in the review (NS = not stated).

  Reference                                   Publication year   Selectionbias   Performancebias   Detectionbias   Attritionbias   Reportingbias
  ------------------------------------------- ------------------ --------------- ----------------- --------------- --------------- ---------------
  **Randomized controlled trials**                                                                                                 
                                                                                                                                   
  **Periodontitis**                                                                                                                
                                                                                                                                   
  Gong et al. ([@B18])                        2013               −               −                 −               −               −
                                                                                                                                   
  **Rhinosinusitis**                                                                                                               
                                                                                                                                   
  Wallwork et al. ([@B26])                    2006               −               −                 −               −               −
                                                                                                                                   
  **Asthma bronchiale**                                                                                                            
                                                                                                                                   
  Cameron et al. ([@B27])                     2013               NS              −                 −               \+              \+
  He et al. ([@B28])                          2009               \+              NS                NS              NS              \+
  Piacentini et al. ([@B29])                  2007               −               −                 −               \+              \+
  Fonseca-Aten et al. ([@B30])                2006               \+              −                 −               −               \+
  Amayasu et al. ([@B31])                     2000               \+              −                 −               −               −
  Kraft et al. ([@B32])                       2002                +              −                 −               −                + 
  Simpson et al. ([@B33])                     2008               −               −                 −               −                + 
  Wang et al. ([@B34])                        2012               \+              NS                NS              NS              −
  Shoji et al. ([@B35])                       1999               \+              −                 −               −               \+
                                                                                                                                   
  **Bronchiectasis**                                                                                                               
                                                                                                                                   
  Yalcin et al. ([@B38])                      2006               \+              NS                NS              −               \+
  Liu et al. ([@B39])                         2014               \+              \+                \+              −               \+
                                                                                                                                   
  **Chronic obstructive pulmonary disease**                                                                                        
  Parnham et al. ([@B40])                     2005               \+              −                 −               −               −
  Banerjee et al. ([@B41])                    2004               \+              −                 −               −               −
  He et al. ([@B42])                          2010               \+              −                 −               −               −
                                                                                                                                   
  **Cystic fibrosis**                                                                                                              
                                                                                                                                   
  Ratjen et al. ([@B50])                      2012               −               −                 −               −               −
  Equi et al. ([@B51])                        2002               \+              −                 −               −               \+
  Doğru et al. ([@B52])                       2009               \+              −                 −               −               −
                                                                                                                                   
  **Diabetic nephropathy**                                                                                                         
  Tone et al. ([@B60])                        2011               \+              \+                \+              −               −
                                                                                                                                   
  **Coronary atherosclerosis**                                                                                                     
  Berg et al. ([@B55])                        2003               \+              −                 −               −               −
                                                                                                                                   
  **Healthy volunteers**                                                                                                           
  Criqui et al. ([@B57])                      2000               \+              −                 −               −               −
                                                                                                                                   
  **Case--control studies**                                                                                                        
                                                                                                                                   
  **Blepharitis**                                                                                                                  
  Zhang et al. ([@B16])                       2015               \+              \+                \+              −               −
                                                                                                                                   
  **Diffuse panbronchiolitis**                                                                                                     
  Oda et al. ([@B44])                         1994               \+              \+                \+              −               −
  Kadota et al. ([@B45])                      1993               \+              \+                \+              −               −
  Katsuki et al. ([@B46])                     1996               \+              \+                \+              −               −
  Ichikawa et al. ([@B47])                    1992               \+              \+                \+               +              −
  Sakito et al. ([@B48])                      1996               \+              \+                \+              −               −
  Umeki ([@B49])                              1993               −               \+                \+              −               −

Immunological Markers Analyzed {#S3-2}
------------------------------

A total of 47 different immunological markers were investigated. On average, four markers were investigated per study resulting in a total of 186 measurements (Table [3](#T3){ref-type="table"}; Figure [2](#F2){ref-type="fig"}). The immunological markers were classified into groups: cell counts (*n* = 9 markers/41 total measurements), neutrophil function (*n* = 6/25), eosinophil function (*n* = 2/7), macrophage function (*n* = 1/1), cytokine concentrations (*n* = 16/81), inflammatory proteins (*n* = 6/8), cell adhesion molecules (*n* = 2/3), molecules involved in inflammatory signaling pathway (*n* = 1/1), and other markers (*n* = 5/5, alpha-2-macroglobulin, beta-2-microglobulin, high-sensitivity C reactive protein, calprotectin, nasal nitric oxide).

###### 

Macrolide-induced changes in immunological markers based on 43 studies in humans.

  -------------------------------
  ![](fimmu-09-00302-it001.jpg)
  -------------------------------

![Overview of immunomodulatory effects of macrolides based on studies summarized in Table [1](#T1){ref-type="table"}. Arrows depict excreted proteins, boxes depict cell counts or functions.](fimmu-09-00302-g002){#F2}

Overall, a decrease in immunological markers, number, or function was more frequently observed than an increase (139 measurements vs 19). No change of immunological markers reported in 11 immunological markers (28 measurements) in 7 studies. The most frequently reported macrolide-induced changes were a decrease in interleukin (IL)-8 concentration (*n* = 21), neutrophil count (*n* = 15), tumor necrosis factor-alpha (TNF-alpha) (*n* = 9), neutrophil elastase (*n* = 8), IL-1beta (*n* = 7), eosinophilic cationic protein (ECP, *n* = 6), IL-6 (*n* = 5), matrix metalloproteinase 9 (MMP-9) (*n* = 5), and oxidative burst activity (*n* = 5).

Immunomodulatory effects were investigated for four types of macrolides, including CAM (*n* = 73), AZM (*n* = 69), ERM (*n* = 27), and RXM (*n* = 17). AZM was more frequently associated with no influence on the immunological markers investigated (21/69) compared to any of the other macrolides (Table [4](#T4){ref-type="table"}).

###### 

Number of measurements and changes in immunological markers for each macrolide.

          Decrease/non-significant decrease   Increase/non-significant increase   No change   Total
  ------- ----------------------------------- ----------------------------------- ----------- -------
  AZM     33/4                                10/1                                21          69
  CAM     52/12                               1/2                                 6           73
  ERM     21/0                                4/1                                 1           27
  RXM     17/0                                0/0                                 0           17
  Total   123/16                              15/4                                28          186

Immunomodulatory Properties in Different Diseases {#S3-3}
-------------------------------------------------

In the following, the immunomodulatory properties of macrolides are summarized and categorized by the disease in which they were investigated (Table [1](#T1){ref-type="table"}).

Blepharitis {#S3-4}
-----------

Blepharitis is a common chronic inflammation of the eye lid leading to dry, itchy, and erythematous eyes. Anterior blepharitis is often associated with bacterial infections, while posterior blepharitis is linked to dysfunction of Meibomian glands. Many studies report clinical improvement in patients with blepharitis treated with topical AZM, due to a decrease in secretions and plugging of the Meibomian glands but did not investigate the underlying immunological mechanisms. The one study which did investigate immunological markes shows that concentrations of IL-1beta, IL-8, and MMP-9 in conjunctival cells of patients with blepharitis are higher than in healthy controls ([@B16]). Concentrations of these cytokines decrease with local AZM treatment, but return to pre-treatment levels after discontinuation ([@B16]).

Periodontitis {#S3-5}
-------------

Periodontitis is an inflammatory process of the gums with a complex pathogenesis including microorganisms as well as neutrophils, macrophages and fibroblasts. One key immunological mechanism underlying the pathogensis of periodontitis has been described as a TNF-alpha-induced increase in vascular endothelial growth factor (VEGF) leading to an aberrant angiogenesis ([@B61]). Both AZM and RXM decreased TNF-alpha and VEGF concentrations as well as other cytokines including IL-1beta, IL-8, and transforming growth factor beta (TGF-beta) in gingival crevicular fluid ([@B17], [@B18]). Since oral bacteria play an important role in periodontitis, however, some of the some of the benefits of macrolides may be attributable to antimicrobial rather than to immunomodulatory effects.

Chronic Rhinosinusitis and Nasal Polyposis {#S3-6}
------------------------------------------

Chronic rhinosinusitis (CRS) with nasal polyps is characterized by a T helper (Th) 2 cells-dominated inflammation with upregulation of IL-4, IL-5, and IL-13 and an increase in eosinophil count, ECP, and immunoglobulin E. CRS without nasal polyps is characterized by Th1-dominated inflammation with upregulation of IL-2, TGF-beta, and IFN-gamma. Studies in patients with CRS treated with CAM and RXM show a significant reduction in macrophage, neutrophil, and eosinophil counts and concentrations of neutrophil elastase, ECP, CC-chemokine ligand-5 (CCL-5), IL-1beta, IL-6, IL-8, interferon (IFN)-gamma, TNF-alpha, myeloperoxidase (MPO), and alpha-macroglobulin in nasal secretions ([@B19]--[@B23], [@B25], [@B26], [@B62]). One of the postulated mechanisms by which macrolides inhibit the development of nasal polyps is through their anti-oxidative effects inhibiting the TGF-beta-induced production of reactive oxygen species ([@B24]). However, the immunomodulatory mechanisms differ in allergic and non-allergic nasal polyposis patients. While CAM reduces IL-6 and CCL-5 in all patients, it reduces IL-1beta and IL-6 only in patients with allergic CRS and TNF-alpha and ECP only in patients with non-allergic CRS ([@B19], [@B20]).

Asthma {#S3-7}
------

Asthma is characterized by chronic airway inflammation, reversible airway obstruction, and airway hyper-responsiveness. In eosinophilic asthma, eosinophils, mast cells, and Th2-mediated inflammation play an important role. Concentrations of IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, vascular cell adhesion molecule-1, CC chemokines, and granulocyte macrophage colony-stimulating factor (GM-CSF) are elevated. In severe asthma, in addition to eosinophils, increased neutrophils and IL-8 concentrations are found in airways. In patients with asthma, AZM, CAM, and RXM decrease eosinophil and neutrophil counts, inhibit neutrophil migration and oxidative burst activity in phagocytes, decrease concentrations of neutrophil elastase, ECP, IL-1, IL-4, IL-5, IL-8, IL-10, IL-12, MMP-9, TNF-alpha, and INF-gamma in nasopharyngeal secretions, sputum, or bronchoalveolar lavage (BAL) samples ([@B27]--[@B30], [@B32]--[@B36]). In addition, CAM and RXM also decrease the eosinophil counts and concentrations of ECP in blood and inhibit oxidative burst activity in phagocytes ([@B31], [@B35], [@B36]).

Bronchiectasis {#S3-8}
--------------

Bronchiectasis is characterized by permanent enlargement of bronchi and cytokines play an important role in the pathogenesis. In BAL samples of patients with bronchiectasis, elevated concentrations of IL-1beta and IL-8, as well as Th17-cytokines (IL-17A and IL-23), are found. In this setting, CAM and RXM lead to a decrease in total cell and neutrophil counts, concentrations of neutrophil elastase, IL-8, and MMP-9 in sputum or BAL of patients with bronchiectasis ([@B38], [@B39]). Interestingly, in BAL samples, these drugs significantly increase macrophage counts ([@B38]). Furthermore, macrolides lead to a decrease in peripheral blood Th17 cells and IL-17 concentrations ([@B37]).

Chronic Obstructive Pulmonary Disease {#S3-9}
-------------------------------------

Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation of lung parenchyma and peripheral airways with an increase in alveolar macrophages, neutrophils, T cells (predominantly Th1-, and Th17- cells), and innate lymphoid cells. These cells, as well as structural cells, such as epithelial cells, endothelial cells, and fibroblasts, secrete a variety of pro-inflammatory cytokines. Although most patients with COPD have a predominantly neutrophilic inflammation, some also have elevated eosinophil counts in sputum. Oxidative stress plays a key role in COPD, and can result in activation of the pro-inflammatory transcription factor nuclear factor (NF)-kappaB. Moreover, COPD is associated with increased apoptosis and defective phagocytosis in the airways. In patients with COPD, IL-1beta, IL-4, IL-8, and TNF-alpha concentrations in blood are elevated, while IL-10 concentrations are lower compared to healthy adults. In patients with COPD, AZM leads to a decrease in white blood cell and platelet counts and concentrations of CRP, IL-8, E-selectin, and lactoferrin in blood ([@B40]). By contrast, macrolides increase neutrophil oxidative burst and neutrophil glutathione peroxidase activity in blood ([@B40]). In the sputum of COPD patients, CAM and ERM lead to a significant decrease in total cell and neutrophil count and inhibit neutrophil chemotaxis and decrease concentrations of neutrophil elastase ([@B41], [@B42]).

Diffuse Panbronchiolitis {#S3-10}
------------------------

Diffuse panbronchiolitis (DPB) is a chronic distal airway inflammation characterized by diffuse micronodular pulmonary lesions mostly consisting of neutrophils. Neutrophils and epithelial cells produce IL-8, which is an important chemotactic factor to attract more neutrophils. The neutrophil count in BAL samples of patients with DPB correlates to the concentrations of IL-1beta and IL-8 ([@B48]). ERM reduces IL-1beta concentrations in BAL samples of patients with DPB which leads to a subsequent reduction of IL-8 concentrations and a decrease in neutrophil count and neutrophil chemotactic activity ([@B44]--[@B48], [@B63]). Furthermore, ERM treatment also results in a decrease in lymphocyte count, IL-2, interferon-gamma, and to increase in CD4/CD8 ratio, IL-4, IL-5, IL-13 in BAL samples of patients with DPB ([@B43]).

Cystic Fibrosis {#S3-11}
---------------

In patients with cystic fibrosis (CF), chronic airway inflammation results from cytokines secreted by epithelial and immune cells, which leads to neutrophil influx into airways. The release of neutrophil proteases, including neutrophil elastase, contributes to the development of bronchiectasis. Sustained inflammation is mainly due to an increase in the transcription of NF-kappaB activity, which leads to an increase in IL-8 production. These immunological mechanisms are influenced by AZM and CAM, which in CF-patients lead to a decrease in neutrophil count, concentrations of neutrophil elastase, IL-4, IL-8, TNF-alpha, and INF-gamma, and to an increase in numbers of macrophages in BAL samples or in sputum ([@B51]--[@B53]). In CF-patients macrolides also lead to a decrease in neutrophil count, concentrations of IL-4, IL-8, TNF-alpha, MPO, high-sensitivity C reactive protein, serum amyloid A, and calprotectin in blood ([@B50], [@B53]).

Discussion {#S4}
==========

Macrolides are important therapeutic options in the treatment of many chronic inflammatory diseases because of their immunomodulatory effects. To understand the mechanisms underlying these effects, we reviewed all human studies that analyzed the influence of macrolides on immunological markers. The non-antimicrobial effects of macrolides are extensive and range from changes in cell counts and function, up- and downregulation of cytokine production to expression of adhesion molecules.

The most frequently and consistently reported immunomodulatory effect of macrolides is a reduced neutrophilic inflammation. Reduced numbers of neutrophils and inhibition of neutrophilic function lead to lower concentrations of neutrophil elastase and IL-8, and ultimately to a decrease in tissue injury. Furthermore, macrolides also reduce IL-1beta concentrations, another key mediator of the inflammatory response that is most abundantly produced by monocytes and macrophages. Evidence from animal and *in vitro* studies show that the inhibition of the key pro-inflammatory cytokines IL-8 and IL-1beta results from macrolides' ability to alter intracellular signaling, particularly through the inhibition of NF-kappaB activation and expression of activator protein-1 ([@B64]--[@B66]). Notably, this effect has been observed in the absence of an infectious agent.

On the basis of these observed *in vitro* immunological effects of macrolides, patients with diseases mediated by neutrophilic inflammation such as periodontitis, severe asthma, DPB, bronchiectasis, COPD, and CF should benefit from treatment with this class of antibiotics. Indeed, clinically beneficial effects have been shown in randomized controlled studies in patients with COPD and CF with improved symptom scores, respiratory function and decreased frequency of exacerbations ([@B67]--[@B69]). For DPB, bronchiectasis and asthma, however, there is an absence of randomized controlled studies showing clinical beneficial effects of macrolides ([@B70]--[@B72]).

Macrolides are more commonly and consistently reported to inhibit neutrophilic than eosinophilic function. This is consistent with clinical studies that show patients with eosinophil-driven chronic inflammatory diseases associated with increased IgE (such as CRS or atopic asthma) have significantly lower improvement rates with macrolide treatment than those with normal serum IgE ([@B26], [@B62], [@B73]). Although the effect of macrolides on eosinophils has been less commonly investigated, a few studies report decreased eosinophil counts, and concentration of ECP (a ribonuclease secreted by eosinophils responsible for local cytotoxic effect). This suggests that there may be a role for the use of macrolides in allergic chronic inflammatory diseases ([@B43], [@B74], [@B75]). The possible influence of macrolides on eosinophilic inflammation is further supported by the finding that Th2 cytokines, such as IL-4 and IL-5, are more frequently reduced than Th1 cytokines, such as IL-2 and INF-gamma ([@B19], [@B20], [@B22], [@B32], [@B42], [@B43], [@B53], [@B55], [@B56]). The stronger effect of macrolides on Th2 compared with Th1 responses is further supported by evidence from animal and *in vitro* studies ([@B74], [@B75]). However, some of the anti-inflammatory effects might also be explained through their antibiotic effect on (undiagnosed) pathogens which trigger and sustain inflammation.

It is likely that immunomodulatory effects vary between different macrolides. Although some studies included more than one macrolide, none of the human studies directly compared different macrolides. Interestingly, AZM was less frequently associated with changes in measured immunological markers compared to the other macrolides. However, most of these studies were either in healthy volunteers or AZM was administered for only a few days ([@B56]--[@B58], [@B76]). By contrast, clinical studies in patients with CF suggest that AZM, but not CAM, leads to an improvement in respiratory function and reduction in pulmonary exacerbations ([@B69], [@B77]). *In vitro* studies comparing the immunomodulatory effects of different macrolides suggest that CAM has less immunomodulatory activity compared to other macrolides. For example, RXM, but not CAM or ERM, was shown to decreased chemotaxis of Th1 and Th2 cells ([@B78]). Similarly, CAM had a significantly weaker effect on reducing IL-6 production by human macrophages than ERM ([@B79]). Furthermore, another study showed that AZM, but not CAM or RXM, inhibits IL-1alpha and IL-1beta production ([@B80]).

Immunomodulatory effects of macrolides have been described with the recommended dose for antimicrobial treatment. Macrolides have excellent tissue penetration compared to other classes of antibiotics resulting in tissue concentrations generally exceeding serum concentrations (except for RXM). For the immunomodulatory effects macrolides' ability to accumulate in neutrophils and macrophages is particularly important. Concentrations in macrophages have been shown to be 400- to 800-fold higher compared to serum for CAM and AZM and 5- to 100-fold higher in tissue compared to serum for ERM, CAM and AZM ([@B81]--[@B85]). This drug accumulation in immune cells may result in immunomodulatory effects occurring at lower doses and lasting longer compared to the antimicrobial effects. The relationship between macrolide dose and immunomodulatory effect is, therefore, an interesting avenue for future research.

The main limitation of this review is the heterogeneity of study populations, underlying diseases, type of macrolide and methods used to assess the immunomodulatory effect. A further limitation is selection and reporting bias and based on study types other biases including carry-over effect in cross-over trials and recall bias in case--control studies.

In summary, there is substantial evidence that macrolides exhibit immunomodulatory effects through inhibition of neutrophilic inflammation and macrophage activation. However, there is considerable heterogeneity between studies and in the immunological markers measured. Further studies will help delineate the exact mechanisms underlying the immunomodulatory properties of macrolides and the relative activity of different macrolides. This will enable the optimal use of this class of antibiotics in the treatment of chronic inflammatory diseases.
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